Azathioprine active metabolite concentrations in inflammatory bowel disease

被引：0
|
作者：
Wright, S
Sanders, DS
Lennard, L
Lobo, AJ
机构：
[1] Univ Sheffield, Royal Hallamshire Hosp, Sect Med & Pharmacol, Sheffield S10 2JF, S Yorkshire, England
[2] Royal Hallamshire Hosp, Dept Gastroenterol, Sheffield S10 2JF, S Yorkshire, England
来源：
GUT | 2003年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
48
引用
收藏
页码：A13 / A13
页数：1
相关论文
共 50 条
  • [1] Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease
    Wright, S
    Sanders, DS
    Lobo, AJ
    Lennard, L
    [J]. GUT, 2004, 53 (08) : 1123 - 1128
  • [2] Azathioprine metabolism in inflammatory bowel disease: Active metabolite concentrations and incidence of noncompliance
    Webster, S
    Sanders, DS
    Lobo, AJ
    Lennard, L
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 440P - 440P
  • [3] Steady-state azathioprine metabolite concentrations in inflammatory bowel disease
    Wright, S
    Sanders, DS
    Lobo, AJ
    Lennard, L
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) : 436 - 437
  • [4] Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease
    Stevens, T
    Achkar, JP
    Easley, K
    Brzezinski, A
    Lashner, B
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (06) : 601 - 606
  • [5] Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation
    Lin, Rongfang
    Lin, Weiwei
    Wang, Changlian
    Dong, Jiashan
    Zheng, Weiwei
    Zeng, Dayong
    Liu, Yiwei
    Lin, Cuihong
    Jiao, Zheng
    Huang, Pinfang
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 (03) : 482 - 492
  • [6] Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease
    Gearry, RB
    Barclay, ML
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (08) : 1149 - 1157
  • [7] Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations
    Ivanka Curkovic
    Katharina M. Rentsch
    Pascal Frei
    Michael Fried
    Gerhard Rogler
    Gerd A. Kullak-Ublick
    Alexander Jetter
    [J]. European Journal of Clinical Pharmacology, 2013, 69 : 1521 - 1531
  • [8] Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations
    Curkovic, Ivanka
    Rentsch, Katharina M.
    Frei, Pascal
    Fried, Michael
    Rogler, Gerhard
    Kullak-Ublick, Gerd A.
    Jetter, Alexander
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (08) : 1521 - 1531
  • [9] HOW MUCH ALLOPURINOL IS NEEDED TO OPTIMIZE AZATHIOPRINE THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH INADEQUATE THIOPURINE METABOLITE CONCENTRATIONS?
    Curkovic, I.
    Rentsch, K.
    Fried, M.
    Rogler, G.
    Kullak-Ublick, G. A.
    Jetter, A.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 : 30 - 30
  • [10] High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine
    Nguyen, T. -M. -H.
    Le Gall, C.
    Lachaux, A.
    Boulieu, R.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (04) : 275 - 281
12345